Daily non-political popular news in brief.
Ā£1.2 million grant could lead to ādesignerā drugs
07-03-2007 · University of BathScientists from the Department of Pharmacy & Pharmacology at the University of Bath have been awarded Ā£1.2 million to help better understand how the cells in our body communicate using āmolecular messengersā.
Read more »
Keywords: million, grant, lead, designerā, drugs, drug
« Previous | Next »
Similar news on "Ā£1.2 million grant could lead to ādesignerā drugs":
- Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
12-07-2007 · Brookhaven National Laboratory
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced positive initial top-line results from an investigator-initiated Phase II double-blind, placebo-controlled trial, which demonstrates that vigabatrin is effective for the treatment of cocaine addiction. Catalyst's lead compound, CPP-109, is bioequivalent to vigabatrin.
Similar news · Read more »
- UT Southwestern earns $34 million NIH grant to foster patient-oriented research
09-18-2007 · UT Southwestern Medical Center
UT Southwestern Medical Center will receive $34 million from the National Institutes of Health to lead a wide-ranging collaborative initiative aimed at speeding the transfer of laboratory discoveries to new therapies that improve human health.
Similar news · Read more »
- Unusually stable glasses may benefit drugs, coatings
12-08-2006 · EurekAlert!
A new approach to making remarkably stable glassy materials from organic molecules, developed by researchers from the University of Wisconsin-Madison and the NIST Center for Neutron Research, could lead to novel coatings and to improvements in drug delivery.
Similar news · Read more »
- Catalyst Pharmaceutical Partners, Inc. Initiates U.S. Phase II Clinical Trial of CPP-109 in Patients With Cocaine Dependence
07-10-2007 · Brookhaven National Laboratory
Catalyst Pharmaceutical Partners, Inc., a specialty pharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that it has initiated its randomized, double-blind, placebo-controlled U.S. Phase II clinical trial of CPP-109 in patients with cocaine dependence. CPP-109, an orally administered, small molecule drug which inhibits psychostimulant-induced dopamine release, is Catalyst's lead compound, vig
Similar news · Read more »
- New forecasting tool could reduce drug development costs
02-01-2007 · EurekAlert!
It now costs more than $800 million to develop a new drug. But what if pharmaceutical companies could predict which experimental drugs will ultimately get FDA approval, and which will ultimately fail? Researchers present a forecasting model that could potentially save hundreds of millions of dollars per new drug. They also urge more data sharing by the drug industry to improve the accuracy of forecasting, allowing more medical discoveries to be brought to the bedside.
Similar news · Read more »
- Tequila raw ingredient being developed into drug-carrier that targets colon diseases
03-27-2007 · EurekAlert!
Compounds derived from the blue agave, a fruit used to make tequila, show promise as a natural, more effective way to deliver drugs to the colon than conventional drug-carriers, according to chemists at the University of Guadalajara in Mexico. The discovery could lead to improved treatments for a variety of colon diseases, including ulcerative colitis, irritable bowel and cancer, they say. The research will be presented in March at the American Chemical Society national meeting.
Similar news · Read more »
- Controlling prescription drug expenditures: a case report of success
08-07-2007 · EurekAlert!
As national spending on prescription drugs rose faster than any other segment of health-care spending, the health plan at Wake Forest University Baptist Medical Center was able to maintain constant spending, resulting in savings of more than $6.6 million over three years.
Similar news · Read more »
- Discovery of an HIV inhibitor in human blood points to new drug class
04-19-2007 · EurekAlert!
A new study has pinpointed a natural ingredient of human blood that effectively blocks HIV-1, the virus predominantly responsible for human AIDS, from infecting immune cells and multiplying. The virus blocker might play a role in the progression of HIV to full-blown AIDS and -- because it works in a different way than existing antiretroviral inhibitors -- could lead to the development of another class of drugs in the fight against the pandemic disease.
Similar news · Read more »
- Nanoparticles hitchhike on red blood cells: a potential new method for drug delivery
06-27-2007 · EurekAlert!
Polymeric nanoparticles are excellent carriers for delivering drugs. However, they are quickly removed from the blood, sometimes in minutes, rendering them ineffective in delivering drugs. This study reports that nanoparticles can be forced to remain in circulation by attaching to red blood cells. Prolonged circulation of nanoparticles in the blood may potentially open new opportunities for the treatment of conditions such as cancer and heart disease.
Similar news · Read more »
- MIT model could predict cells' response to drugs
07-30-2007 · EurekAlert!
MIT researchers have developed a model that could predict how cells will respond to targeted drug therapies. Models based on this approach could help doctors make better treatment choices and drug developers identify the ideal compound. In addition, the model could help test the effectiveness of drugs for a wide range of diseases, including cancer, arthirtis, and immune system disorders.
Similar news · Read more »
